Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial diseasePicotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.

Smith, Donald A MD, MPH (commentator)
Neri Serneri, GG
Coccheri, S
Marubini, E
et al,

Mount Sinai School of Medicine, New York, New York, USA

Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845–52.Neri SerneriGGCoccheriSMarubiniEet alPicotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.Eur Heart J2004251845-52Q In patients with type 2 diabetes mellitus and peripheral arterial disease (PAD), is picotamide better than aspirin for preventing all cause mortality and major cardiovascular (CV) events?

For correspondence: Dr S Coccheri, University of Bologna, Bologna, Italy. [email protected]

Source of funding: Novartis S.p.a.

Evidence Based Medicine 10(3):p 79, June 2005.

Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Haematology ★★★★★★☆ Endrocrine ★★★★★★☆